The global gout therapeutics market size is expected to reach USD 6,304.8 million by 2026 according to this new study. The report “Gout Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Drug Class (Non-steroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids, Colchicine, Urate Lowering Agents) Disease Condition (Acute, Chronic); By Regions, Segments & Forecast, 2020-2026” gives a detailed insight into current market dynamics and provides analysis on future market growth.
The incidence and prevalence of gout has increased over two-fold in past 20 years. This growth combined with increasing occurrence of comorbid conditions and cardiovascular risk factors represents a significant public health challenge. Globally, the developed countries tend to have a higher burden of gout compared to the developing countries, and also have increasing prevalence of this disease. There are various factors including genetic history, and ethnicity that could lead to occurrence of gout. Also, socioeconomic and dietary factors, as well as comorbidities and medications that can influence uric acid levels and facilitate MSU crystal formation, are also important in determining the risk of developing clinically evident gout.
Increasing geriatric population, and growing prevalence of this condition associated with this growing elderly population are the primary factors driving the growth of the industry. According to a study published in the Modern Medicine, elder population are more prone to develop tophi and the prevalence of metabolic syndrome among the elder population with gout was 62%. Currently, the geriatric population is growing at an extraordinary rate. According to the data published by the United Nations in 2012, global geriatric population was nearly 809.4 million in 2011 and is anticipated to grow more than double and reach over 2,000 million by 2050.
Furthermore, growing prevalence of this condition across the globe, increasing research and development activities, growing number of product approvals, and increasing public and private investments are some other factors driving the growth of the market during the forecast period. Recently, in New Zealand, the HRC funded Professor Lisa Stamp at the University of Otago to lead the first-ever randomized controlled trial demonstrating an improved dosing strategy using allopurinol to help more patients to manage their gout symptoms. Also, in 2019 researchers at Washington State University Health Sciences Spokane and elsewhere identified a new therapeutic target for the treatment of gout. Such growing research studies are fueling the growth of the market during the forecast period.
However, factors such as patent expiry of blockbuster products, increasing competition in the generic sector and high cost of the newly launched drugs are likely to hinder the growth of this market during the forecast period. The cost associated with gout therapies is poised to increase dramatically due to federal policy decisions and pipeline developments. Also, patent expiry of major blockbuster agents and expected launch of generic version are likely to restrain the growth of the market during the forecast period. Entry of generic after its patent expiry would decline the revenue in future. Hence, high cost of the products and patent expiry of the medicines is a key factor to restrain the growth of the market.
The global market is dominated by North America as the countries such as US and Canada have a large patient base, and also significant number of research activities are being conducted in this region. Many companies operating in this market segment are based in the US, and hence new products are primarily introduced in this regional segment. Gout affects around 8.3 million people in the United States, with prevalence in range of the 1-4%. The prevalence of gout is higher in African Americans as compared to Caucasians, and is projected to be increasing across all demographics in coming few years. Furthermore, government is also taking various measures to generated awareness and provide better healthcare facilities to the patient suffering with gout in this region.
Furthermore, Europe also has a significant share in the global industry. Various international companies have been launching new products in the European market. For instance, in August 2018, Grünenthal received European approval for Duzallo (lesinurad/allopurinol) and extended its gout portfolio. However, Asia-Pacific is projected to witness a fastest growth during the forecast period. This highest growth is mainly anticipated due to the presence of several high economically growing countries such as India, China, South Korea, and other South Asian countries. Increasing number of people linked with smoking and alcohol consumption, growing population, increasing need for effective therapies, and growing expansion of local and international players in this regional segment are also fueling the growth of gout therapeutics market in this region.
The key players in the industry include AstraZeneca, Horizon Pharma Plc, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Novartis AG, Merck & Co. Inc., Teijin Pharma Limited, Regeneron Pharmaceuticals, Inc, Ironwood Pharmaceuticals, Inc., JW Pharmaceutical, Selecta Biosciences, Inc., and Grunenthal Group among others.
The publisher has segmented the Gout Therapeutics market report on the basis of level, application, material type, product type, product style and region
Non-steroidal Anti-Inflammatory Drugs (NSAIDs)
Corticosteroids
Colchicine
Urate Lowering Agents
Acute
Chronic
North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
Belgium
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Australia
Rest of Asia-Pacific
Latin America
Brazil
Mexico
Rest of LATAM
Middle East & Africa
South Africa
Saudi Arabia
Rest of MEA
The incidence and prevalence of gout has increased over two-fold in past 20 years. This growth combined with increasing occurrence of comorbid conditions and cardiovascular risk factors represents a significant public health challenge. Globally, the developed countries tend to have a higher burden of gout compared to the developing countries, and also have increasing prevalence of this disease. There are various factors including genetic history, and ethnicity that could lead to occurrence of gout. Also, socioeconomic and dietary factors, as well as comorbidities and medications that can influence uric acid levels and facilitate MSU crystal formation, are also important in determining the risk of developing clinically evident gout.
Increasing geriatric population, and growing prevalence of this condition associated with this growing elderly population are the primary factors driving the growth of the industry. According to a study published in the Modern Medicine, elder population are more prone to develop tophi and the prevalence of metabolic syndrome among the elder population with gout was 62%. Currently, the geriatric population is growing at an extraordinary rate. According to the data published by the United Nations in 2012, global geriatric population was nearly 809.4 million in 2011 and is anticipated to grow more than double and reach over 2,000 million by 2050.
Furthermore, growing prevalence of this condition across the globe, increasing research and development activities, growing number of product approvals, and increasing public and private investments are some other factors driving the growth of the market during the forecast period. Recently, in New Zealand, the HRC funded Professor Lisa Stamp at the University of Otago to lead the first-ever randomized controlled trial demonstrating an improved dosing strategy using allopurinol to help more patients to manage their gout symptoms. Also, in 2019 researchers at Washington State University Health Sciences Spokane and elsewhere identified a new therapeutic target for the treatment of gout. Such growing research studies are fueling the growth of the market during the forecast period.
However, factors such as patent expiry of blockbuster products, increasing competition in the generic sector and high cost of the newly launched drugs are likely to hinder the growth of this market during the forecast period. The cost associated with gout therapies is poised to increase dramatically due to federal policy decisions and pipeline developments. Also, patent expiry of major blockbuster agents and expected launch of generic version are likely to restrain the growth of the market during the forecast period. Entry of generic after its patent expiry would decline the revenue in future. Hence, high cost of the products and patent expiry of the medicines is a key factor to restrain the growth of the market.
The global market is dominated by North America as the countries such as US and Canada have a large patient base, and also significant number of research activities are being conducted in this region. Many companies operating in this market segment are based in the US, and hence new products are primarily introduced in this regional segment. Gout affects around 8.3 million people in the United States, with prevalence in range of the 1-4%. The prevalence of gout is higher in African Americans as compared to Caucasians, and is projected to be increasing across all demographics in coming few years. Furthermore, government is also taking various measures to generated awareness and provide better healthcare facilities to the patient suffering with gout in this region.
Furthermore, Europe also has a significant share in the global industry. Various international companies have been launching new products in the European market. For instance, in August 2018, Grünenthal received European approval for Duzallo (lesinurad/allopurinol) and extended its gout portfolio. However, Asia-Pacific is projected to witness a fastest growth during the forecast period. This highest growth is mainly anticipated due to the presence of several high economically growing countries such as India, China, South Korea, and other South Asian countries. Increasing number of people linked with smoking and alcohol consumption, growing population, increasing need for effective therapies, and growing expansion of local and international players in this regional segment are also fueling the growth of gout therapeutics market in this region.
The key players in the industry include AstraZeneca, Horizon Pharma Plc, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Novartis AG, Merck & Co. Inc., Teijin Pharma Limited, Regeneron Pharmaceuticals, Inc, Ironwood Pharmaceuticals, Inc., JW Pharmaceutical, Selecta Biosciences, Inc., and Grunenthal Group among others.
The publisher has segmented the Gout Therapeutics market report on the basis of level, application, material type, product type, product style and region
Gout Therapeutics Drug Class Outlook (Revenue, USD Million, 2015-2026)
Non-steroidal Anti-Inflammatory Drugs (NSAIDs)
Corticosteroids
Colchicine
Urate Lowering Agents
Gout Therapeutics Disease Condition Outlook (Revenue, USD Million, 2015-2026)
Acute
Chronic
Gout Therapeutics Regional Outlook (Revenue, USD Million, 2015-2026)
North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
Belgium
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Australia
Rest of Asia-Pacific
Latin America
Brazil
Mexico
Rest of LATAM
Middle East & Africa
South Africa
Saudi Arabia
Rest of MEA
Frequently Asked Questions about the Gout Therapeutics Market
What is the estimated value of the Gout Therapeutics Market?
What is the growth rate of the Gout Therapeutics Market?
What is the forecasted size of the Gout Therapeutics Market?
Who are the key companies in the Gout Therapeutics Market?
| Report Attribute | Details |
|---|---|
| No. of Pages | 102 |
| Published | April 2020 |
| Forecast Period | 2020 - 2026 |
| Estimated Market Value ( USD | $ 2442.8 Million |
| Forecasted Market Value ( USD | $ 6304.8 Million |
| Compound Annual Growth Rate | 17.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 12 |
Table of Contents
1. Chapter 1. Introduction1.1. Report Description
1.1.1. Objectives of the Study
1.1.2. Market Scope
1.1.3. Assumptions
1.2. Stakeholders
2. Chapter 2. Executive Summary
2.1. Market Highlights
3. Chapter 3. Research Methodology
3.1. Overview
3.1.1. Data Mining
3.2. Data Sources
3.2.1. Primary Sources
3.2.2. Secondary Sources
4. Chapter 4. Market Analysis
4.1. Overview
4.2. Gout Therapeutics Market Dynamics
4.2.1. Drivers and Opportunities
4.2.1.1. Growing Geriatric Population
4.2.1.2. Increasing incidence and prevalence of gout
4.2.1.3. Growing research and development activities
4.2.2. Restraints and Challenges
4.2.2.1. High cost of new and improved drugs
4.2.2.2. Patent expiry of various blockbuster drugs
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining Power of Suppliers (Moderate)
4.3.2. Threats Of New Entrants: (High)
4.3.3. Bargaining Power Of Buyers (High)
4.3.4. Threats Of Substitute (Moderate)
4.3.5. Rivalry Among The Existing Competitors (Moderate)
4.4. PESTLE Analysis
4.5. Gout Therapeutics Market Industry trends
4.5.1. Newer treatments for gout
4.6. Competitive Ranking Analysis
5. Chapter 5. Gout Therapeutics Market Assessment by Drug Class
5.1. KEY FINDINGS
5.2. Introduction
5.2.1. Global Gout Therapeutics Market, By Type, 2015 – 2026 (USD Million)
5.3. Non-steroidal Anti-Inflammatory Drugs (NSAIDs)
5.3.1. Global Gout Therapeutics NSAIDs Market, by Region, 2015-2026 (USD Million)
5.3.2. North America: Gout Therapeutics NSAIDs Market, by Country, 2015-2026 (USD Million)
5.3.3. Europe: Gout Therapeutics NSAIDs Market, by Country, 2015-2026 (USD Million)
5.3.4. Asia-Pacific: Gout Therapeutics NSAIDs Market, by Country, 2015-2026 (USD Million)
5.3.5. LATAM: Gout Therapeutics NSAIDs Market, by Country, 2015-2026 (USD Million)
5.3.6. MEA: Gout Therapeutics NSAIDs Market, by Country, 2015-2026 (USD Million)
5.4. Corticosteroids
5.4.1. Global Gout Therapeutics Corticosteroids Market, by Region, 2015-2026 (USD Million)
5.4.2. North America: Gout Therapeutics Corticosteroids Market, by Country, 2015-2026 (USD Million)
5.4.3. Europe: Gout Therapeutics Corticosteroids Market, by Country, 2015-2026 (USD Million)
5.4.4. Asia-Pacific: Gout Therapeutics Corticosteroids Market, by Country, 2015-2026 (USD Million)
5.4.5. LATAM: Gout Therapeutics Corticosteroids Market, by Country, 2015-2026 (USD Million)
5.4.6. MEA: Gout Therapeutics Corticosteroids Market, by Country, 2015-2026 (USD Million)
5.5. Colchicine
5.5.1. Global Gout Therapeutics Colchicine Market, by Region, 2015-2026 (USD Million)
5.5.2. North America: Gout Therapeutics Colchicine Market, by Country, 2015-2026 (USD Million)
5.5.3. Europe: Gout Therapeutics Colchicine Market, by Country, 2015-2026 (USD Million)
5.5.4. Asia-Pacific: Gout Therapeutics Colchicine Market, by Country, 2015-2026 (USD Million)
5.5.5. LATAM: Gout Therapeutics Colchicine Market, by Country, 2015-2026 (USD Million)
5.5.6. MEA: Gout Therapeutics Colchicine Market, by Country, 2015-2026 (USD Million)
5.6. Urate Lowering Agents
5.6.1. Global Gout Therapeutics Urate Lowering Agents Market, by Region, 2015-2026 (USD Million)
5.6.2. North America: Gout Therapeutics Urate Lowering Agents Market, by Country, 2015-2026 (USD Million)
5.6.3. Europe: Gout Therapeutics Urate Lowering Agents Market, by Country, 2015-2026 (USD Million)
5.6.4. Asia-Pacific: Gout Therapeutics Urate Lowering Agents Market, by Country, 2015-2026 (USD Million)
5.6.5. LATAM: Gout Therapeutics Urate Lowering Agents Market, by Country, 2015-2026 (USD Million)
5.6.6. MEA: Gout Therapeutics Urate Lowering Agents Market, by Country, 2015-2026 (USD Million)
6. Chapter 6. Gout Therapeutics Market Assessment by Disease Condition
6.1. KEY FINDINGS
6.2. Introduction
6.2.1. Global Gout Therapeutics Market, By Disease Condition, 2015 – 2026 (USD Million)
6.3. Acute Gout
6.3.1. Global Acute Gout Therapeutics Market, by Region, 2015-2026 (USD Million)
6.3.2. North America: Acute Gout Therapeutics Market, by Country, 2015-2026 (USD Million)
6.3.3. Europe: Acute Gout Therapeutics Market, by Country, 2015-2026 (USD Million)
6.3.4. Asia-Pacific: Acute Gout Therapeutics Market, by Country, 2015-2026 (USD Million)
6.3.5. LATAM: Acute Gout Therapeutics Market, by Country, 2015-2026 (USD Million)
6.3.6. MEA: Acute Gout Therapeutics Market, by Country, 2015-2026 (USD Million)
6.4. Chronic
6.4.1. Global Chronic Gout Therapeutics Market, by Region, 2015-2026 (USD Million)
6.4.2. North America: Chronic Gout Therapeutics Market, by Country, 2015-2026 (USD Million)
6.4.3. Europe: Chronic Gout Therapeutics Market, by Country, 2015-2026 (USD Million)
6.4.4. Asia-Pacific: Chronic Gout Therapeutics Market, by Country, 2015-2026 (USD Million)
6.4.5. LATAM: Chronic Gout Therapeutics Market, by Country, 2015-2026 (USD Million)
6.4.6. MEA: Chronic Gout Therapeutics Market, by Country, 2015-2026 (USD Million)
7. Chapter 7. Gout Therapeutics Market Assessment by Geography
7.1. KEY FINDINGS
7.2. Introduction
7.2.1. Gout Therapeutics Market Assessment, By Geography, 2015-2026 (USD Million)
7.3. NORTH AMERICA
7.3.1. North America: Gout Therapeutics Market, by Country, 2015-2026 (USD Million)
7.3.2. North America: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
7.3.3. North America: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
7.3.4. U.S.
7.3.4.1. U.S.: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
7.3.4.2. U.S.: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
7.3.5. Canada
7.3.5.1. Canada: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
7.3.5.2. Canada: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
7.4. EUROPE
7.4.1. Europe: Gout Therapeutics Market, by Country, 2015-2026 (USD Million)
7.4.2. Europe: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
7.4.3. Europe: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
7.4.4. Germany
7.4.4.1. Germany: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
7.4.4.2. Germany: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
7.4.5. UK
7.4.5.1. UK: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
7.4.5.2. UK: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
7.4.6. France
7.4.6.1. France: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
7.4.6.2. France: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
7.4.7. Italy
7.4.7.1. Italy: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
7.4.7.2. Italy: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
7.4.8. Spain
7.4.8.1. Spain: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
7.4.8.2. Spain: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
7.4.9. Belgium
7.4.9.1. Belgium: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
7.4.9.2. Belgium: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
7.4.10. Rest of Europe
7.4.10.1. Rest of Europe: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
7.4.10.2. Rest of Europe: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
7.5. ASIA-PACIFIC
7.5.1. Asia Pacific: Gout Therapeutics Market, by Country, 2015-2026 (USD Million)
7.5.2. Asia Pacific: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
7.5.3. Asia Pacific: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
7.5.4. China
7.5.4.1. China: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
7.5.4.2. China: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
7.5.5. India
7.5.5.1. India: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
7.5.5.2. India: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
7.5.6. Japan
7.5.6.1. Japan: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
7.5.6.2. Japan: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
7.5.7. South Korea
7.5.7.1. South Korea: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
7.5.7.2. South Korea: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
7.5.8. Australia
7.5.8.1. Australia: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
7.5.8.2. Australia: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
7.5.9. Rest of APAC
7.5.9.1. Rest of APAC: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
7.5.9.2. Rest of APAC: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
7.6. LATIN AMERICA
7.6.1. Latin America: Gout Therapeutics Market, by Country, 2015-2026 (USD Million)
7.6.2. Latin America: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
7.6.3. Latin America: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
7.6.4. Brazil
7.6.4.1. Brazil: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
7.6.4.2. Brazil: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
7.6.5. Mexico
7.6.5.1. Mexico: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
7.6.5.2. Mexico: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
7.6.6. Rest of LATAM
7.6.6.1. Rest of LATAM: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
7.6.6.2. Rest of LATAM: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
7.7. MIDDLE EAST AND AFRICA
7.7.1. Middle East & Africa: Gout Therapeutics Market, by Country, 2015-2026 (USD Million)
7.7.2. Middle East & Africa: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
7.7.3. Middle East & Africa: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
7.7.4. South Africa
7.7.4.1. South Africa: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
7.7.4.2. South Africa: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
7.7.5. Saudi Arabia
7.7.5.1. Saudi Arabia: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
7.7.5.2. Saudi Arabia: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
7.7.6. Rest of Middle East and Africa
7.7.6.1. Rest of MEA: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
7.7.6.2. Rest of MEA: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
8. Chapter 8. Competitive Landscape
8.1. Agreements, Collaborations, Product Developments and launch Analysis
8.1.1. Strategic Analysis – Gout Therapeutics Market
8.2. Prouct/Service Launch
8.3. Partnerships/Collaborations/Agreements
8.4. Approvals
8.5. Others
9. Chapter 9. Company Profiles
9.1. AstraZeneca
9.1.1. Business Overview
9.1.2. Financial Snapshot
9.1.3. Products and Services
9.1.4. Recent Developments
9.2. Horizon Pharma Plc
9.2.1. Business Overview
9.2.2. Financial Snapshot
9.2.3. Products and Services
9.2.4. Recent Developments
9.3. Takeda Pharmaceutical Company Limited
9.3.1. Business Overview
9.3.2. Financial Snapshot
9.3.3. Products and Services
9.3.4. Recent Developments
9.4. GlaxoSmithKline plc
9.4.1. Business Overview
9.4.2. Financial Snapshot
9.4.3. Products and Services
9.4.4. Recent Developments
9.5. Novartis AG
9.5.1. Business Overview
9.5.2. Financial Snapshot
9.5.3. Products and Services
9.5.4. Recent Developments
9.6. Merck & Co. Inc.
9.6.1. Business Overview
9.6.2. Financial Snapshot
9.6.3. Products and Services
9.6.4. Recent Developments
9.7. Teijin Pharma Limited
9.7.1. Business Overview
9.7.2. Financial Snapshot
9.7.3. Products and Services
9.7.4. Recent Developments
9.8. Regeneron Pharmaceuticals, Inc.
9.8.1. Business Overview
9.8.2. Financial Snapshot
9.8.3. Products and Services
9.8.4. Recent Developments
9.9. Ironwood Pharmaceuticals, Inc.
9.9.1. Business Overview
9.9.2. Financial Snapshot
9.9.3. Products and Services
9.9.4. Recent Developments
9.10. JW Pharmaceutical
9.10.1. Business Overview
9.10.2. Financial Snapshot
9.10.3. Products and Services
9.10.4. Recent Developments
9.11. Selecta Biosciences, Inc.
9.11.1. Business Overview
9.11.2. Financial Snapshot
9.11.3. Products and Services
9.11.4. Recent Developments
9.12. Grunenthal Group
9.12.1. Business Overview
9.12.2. Financial Snapshot
9.12.3. Products and Services
9.12.4. Recent DevelopmentsList of Tables
Table 1. Drivers and Inhibitors For Global Market
Table 2. Restraints Global Market
Table 3. Global Gout Therapeutics Market, By Type, 2015 – 2026 (USD Million)
Table 4. Global Gout Therapeutics NSAIDs Market, by Region, 2015-2026 (USD Million)
Table 5. North America: Gout Therapeutics NSAIDs Market, by Country, 2015-2026 (USD Million)
Table 6. Europe: Gout Therapeutics NSAIDs Market, by Country, 2015-2026 (USD Million)
Table 7. Asia-Pacific: Gout Therapeutics NSAIDs Market, by Country, 2015-2026 (USD Million)
Table 8. LATAM: Gout Therapeutics NSAIDs Market, by Country, 2015-2026 (USD Million)
Table 9. MEA: Gout Therapeutics NSAIDs Market, by Country, 2015-2026 (USD Million)
Table 10. Global Gout Therapeutics Corticosteroids Market, by Region, 2015-2026 (USD Million)
Table 11. North America: Gout Therapeutics Corticosteroids Market, by Country, 2015-2026 (USD Million)
Table 12. Europe: Gout Therapeutics Corticosteroids Market, by Country, 2015-2026 (USD Million)
Table 13. Asia-Pacific: Gout Therapeutics Corticosteroids Market, by Country, 2015-2026 (USD Million)
Table 14. LATAM: Gout Therapeutics Corticosteroids Market, by Country, 2015-2026 (USD Million)
Table 15. MEA: Gout Therapeutics Corticosteroids Market, by Country, 2015-2026 (USD Million)
Table 16. Global Gout Therapeutics Colchicine Market, by Region, 2015-2026 (USD Million)
Table 17. North America: Gout Therapeutics Colchicine Market, by Country, 2015-2026 (USD Million)
Table 18. Europe: Gout Therapeutics Colchicine Market, by Country, 2015-2026 (USD Million)
Table 19. Asia-Pacific: Gout Therapeutics Colchicine Market, by Country, 2015-2026 (USD Million)
Table 20. LATAM: Gout Therapeutics Colchicine Market, by Country, 2015-2026 (USD Million)
Table 21. MEA: Gout Therapeutics Colchicine Market, by Country, 2015-2026 (USD Million)
Table 22. Global Gout Therapeutics Urate Lowering Agents Market, by Region, 2015-2026 (USD Million)
Table 23. North America: Gout Therapeutics Urate Lowering Agents Market, by Country, 2015-2026 (USD Million)
Table 24. Europe: Gout Therapeutics Urate Lowering Agents Market, by Country, 2015-2026 (USD Million)
Table 25. Asia-Pacific: Gout Therapeutics Urate Lowering Agents Market, by Country, 2015-2026 (USD Million)
Table 26. LATAM: Gout Therapeutics Urate Lowering Agents Market, by Country, 2015-2026 (USD Million)
Table 27. MEA: Gout Therapeutics Urate Lowering Agents Market, by Country, 2015-2026 (USD Million)
Table 28. Global Gout Therapeutics Market, By Deployment Model, 2015 – 2026 (USD Million)
Table 29. Global Acute Gout Therapeutics Market, by Region, 2015-2026 (USD Million)
Table 30. North America: Acute Gout Therapeutics Market, by Country, 2015-2026 (USD Million)
Table 31. Europe: Acute Gout Therapeutics Market, by Country, 2015-2026 (USD Million)
Table 32. Asia-Pacific: Acute Gout Therapeutics Market, by Country, 2015-2026 (USD Million)
Table 33. LATAM: Acute Gout Therapeutics Market, by Country, 2015-2026 (USD Million)
Table 34. LATAM: Acute Gout Therapeutics Market, by Country, 2015-2026 (USD Million)
Table 35. Global Chronic Gout Therapeutics Market, by Region, 2015-2026 (USD Million)
Table 36. North America: Chronic Gout Therapeutics Market, by Country, 2015-2026 (USD Million)
Table 37. Europe: Chronic Gout Therapeutics Market, by Country, 2015-2026 (USD Million)
Table 38. Asia-Pacific: Chronic Gout Therapeutics Market, by Country, 2015-2026 (USD Million)
Table 39. LATAM: Chronic Gout Therapeutics Market, by Country, 2015-2026 (USD Million)
Table 40. MEA: Chronic Gout Therapeutics Market, by Country, 2015-2026 (USD Million)
Table 41. Gout Therapeutics Market Assessment, By Geography, 2015-2026 (USD Million)
Table 42. North America: Gout Therapeutics Market, by Country, 2015-2026 (USD Million)
Table 43. North America: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
Table 44. North America: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
Table 45. U.S.: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
Table 46. U.S.: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
Table 47. Canada: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
Table 48. Canada: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
Table 49. Europe: Gout Therapeutics Market, by Country, 2015-2026 (USD Million)
Table 50. Europe: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
Table 51. Europe: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
Table 52. Germany: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
Table 53. Germany: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
Table 54. UK: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
Table 55. UK: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
Table 56. France: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
Table 57. France: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
Table 58. Italy: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
Table 59. Italy: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
Table 60. Spain: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
Table 61. Spain: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
Table 62. Belgium: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
Table 63. Belgium: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
Table 64. Rest of Europe: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
Table 65. Rest of Europe: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
Table 66. Asia-Pacific: Gout Therapeutics Market, by Country, 2015-2026 (USD Million)
Table 67. Asia-Pacific: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
Table 68. Asia-Pacific: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
Table 69. China: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
Table 70. China: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
Table 71. India: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
Table 72. India: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
Table 73. Japan: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
Table 74. Japan: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
Table 75. South Korea: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
Table 76. South Korea: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
Table 77. Australia: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
Table 78. Australia: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
Table 79. RoAPAC: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
Table 80. RoAPAC: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
Table 81. LATAM: Gout Therapeutics Market, By Country, 2015-2026 (USD Million)
Table 82. LATAM: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
Table 83. LATAM: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
Table 84. Brazil: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
Table 85. Brazil: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
Table 86. Mexico: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
Table 87. Mexico: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
Table 88. RoLATAM: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
Table 89. RoLATAM: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
Table 90. Middle East and Africa: Gout Therapeutics Market, By Country, 2015-2026 (USD Million)
Table 91. Middle East and Africa: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
Table 92. Middle East and Africa: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
Table 93. South Africa: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
Table 94. South Africa: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
Table 95. Saudi Arabia: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
Table 96. Saudi Arabia: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
Table 97. RoMEA: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
Table 98. RoMEA: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
List of Figures
Figure 1. Market Highlights
Figure 2. Integrated Ecosystem
Figure 3. Research Methodology: Top Down Approach
Figure 4. Research Methodology: Bottom Up Approach
Figure 5. Market by Geography
Figure 6. Gout Therapeutics Market – Drivers and Opportunities, Restraints and Challenges
Figure 7. Porter’s Five Forces
Figure 8. Market by Type
Figure 9. Global Gout Therapeutics Market, By Type, 2020 – 2026 (USD Million)
Figure 10. Market by Disease Condition
Figure 11. Global Gout Therapeutics Market, By Disease Condition, 2020 – 2026 (USD Million)
Figure 12. Gout Therapeutics Market Assessment, By Geography, 2020-2026 (USD Milliom)
Figure 13. Strategic Analysis – Gout Therapeutics Market
Companies Mentioned
- AstraZeneca
- Horizon Pharma Plc
- Takeda Pharmaceutical Company Limited
- GlaxoSmithKline plc
- Novartis AG
- Merck & Co. Inc.
- Teijin Pharma Limited
- Regeneron Pharmaceuticals Inc
- Ironwood Pharmaceuticals Inc.
- JW Pharmaceutical
- Selecta Biosciences Inc.
- Grunenthal Group
